Compare FDP & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | HRMY |
|---|---|---|
| Founded | 1886 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1999 | 2020 |
| Metric | FDP | HRMY |
|---|---|---|
| Price | $39.80 | $27.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.70 |
| AVG Volume (30 Days) | 213.0K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | 1.88 | ★ 2.71 |
| Revenue | ★ $4,322,300,000.00 | $868,453,000.00 |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | $3.75 | $12.49 |
| P/E Ratio | $21.47 | ★ $10.32 |
| Revenue Growth | 0.98 | ★ 21.51 |
| 52 Week Low | $29.00 | $25.52 |
| 52 Week High | $43.58 | $40.87 |
| Indicator | FDP | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 33.54 |
| Support Level | $34.76 | $27.66 |
| Resistance Level | $40.75 | $28.99 |
| Average True Range (ATR) | 1.02 | 0.74 |
| MACD | -0.39 | 0.22 |
| Stochastic Oscillator | 5.07 | 34.04 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.